Edesa Biotech, Inc.
332 E. Scott St.
Port Hueneme
California
93401
United States
Tel: 805.488.2800
Website: http://edesabiotech.com/
261 articles about Edesa Biotech, Inc.
-
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
5/19/2022
Edesa Biotech, Inc. announced that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
-
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
5/13/2022
Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2022 and provided an update on its business.
-
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
4/28/2022
Edesa Biotech, Inc. announced that patient recruitment for a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis has been enrolling ahead of schedule.
-
Edesa Biotech Appoints Strategy Expert to Board of Directors
3/29/2022
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the appointment of Jennifer M. Chao to the company's Board of Directors.
-
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
3/24/2022
Edesa Biotech, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused institutional investor of 2,739,727 of the Company's common shares at a purchase price of $3.65 per common share.
-
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
3/22/2022
Edesa Biotech, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,739,727 of the Company's common shares.
-
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
2/17/2022
Edesa Biotech, Inc. today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients.
-
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
2/14/2022
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three months ended December 31, 2021 and provided an update on its business.
-
Edesa Biotech to Join Ontario Bioscience Panel Discussion
1/26/2022
Edesa Biotech, Inc. announced that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.
-
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
1/13/2022
Edesa Biotech, Inc. today reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study.
-
Edesa Biotech Reports Fiscal Year 2021 Results
12/28/2021
Edesa Biotech, Inc. today reported financial results for the fiscal year ended September 30, 2021 and provided an update on its business.
-
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
12/1/2021
Edesa Biotech, Inc. today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis.
-
Edesa Biotech Extends COVID-19 Clinical Study to Poland
11/4/2021
Edesa Biotech, Inc. today announced that Polish regulators have approved a clinical trial application for the investigational use of the company's monoclonal antibody candidate, designated EB05
-
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
10/19/2021
Edesa Biotech, Inc. today announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.
-
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
9/20/2021
Edesa Biotech, Inc. today announced positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.
-
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
9/9/2021
Edesa Biotech, Inc. announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13 to 15, 2021.
-
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
8/26/2021
Edesa Biotech, Inc. today provided an update on a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate as a single-dose therapy for hospitalized COVID-19 patients.
-
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
8/13/2021
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business.
-
Edesa Biotech Extends Dermatitis Study to Canada
7/13/2021
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced that the company has expanded patient enrollment to Canada for the final part of a Phase 2b study evaluating its EB01 drug candidate as a monotherapy for chronic Allergic Contact Dermatitis, or ACD.
-
Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
6/23/2021
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the appointment of a key member to its management team to support the company's expanding manufacturing activities.